Phase I Study of Weekly Oral Miltefosine (Hexadecyl-Phosphocholine) in Cancer Patients

التفاصيل البيبلوغرافية
العنوان: Phase I Study of Weekly Oral Miltefosine (Hexadecyl-Phosphocholine) in Cancer Patients
المؤلفون: H. Sindermann, M. Zafferani, U. Bruntsch, S. Danhauser-Riedl, H. W. Präuer, A. Drozd, Jörg Rüdiger Siewert, M. Peukert
المصدر: Oncology Research and Treatment. 14:392-400
بيانات النشر: S. Karger AG, 1991.
سنة النشر: 1991
مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Miltefosine, business.industry, Nausea, Cancer, Hematology, medicine.disease, Gastroenterology, Surgery, Diarrhea, Oncology, Pharmacokinetics, Internal medicine, Vomiting, medicine, Biological half-life, medicine.symptom, business, Progressive disease, medicine.drug
الوصف: A clinical phase I trial with an oral formulation of miltefosine (MIL) was performed in patients with various advanced malignant diseases. The capsulated drug (50 mg or 100 mg capsules) was given once a week over a period of twelve hours with a starting dose of 100 mg (2x50 mg). Dose escalation proceeded up to 300 mg per week. At least three patients were treated at each dose level for eight weeks or until progressive disease or dose limiting toxicity occurred. 34 patients entered this study with 26 patients completing one eight-week course of therapy. Only gastrointestinal side effects were seen, namely nausea and vomiting or diarrhea up to grade III (WHO). Severity of these side effects was dose-related, but there was considerable individual variation. MTD was reached at the 300 mg dose level. Pharmacokinetic studies performed at this dose level showed peak plasma levels of approx. 15 nmol/ml and a plasma half life in excess of eight days after application on one single day. No objective remission has been seen in the patients of this study.
تدمد: 2296-5262
2296-5270
DOI: 10.1159/000217014
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::c9d2e3b94db13a5319c6ecbe6a1764b4
https://doi.org/10.1159/000217014
Rights: CLOSED
رقم الانضمام: edsair.doi...........c9d2e3b94db13a5319c6ecbe6a1764b4
قاعدة البيانات: OpenAIRE
الوصف
تدمد:22965262
22965270
DOI:10.1159/000217014